Terry E. Goldberg, PhD
Areas of Expertise / Conditions Treated
- Professor of Medical Psychology (in Psychiatry)
I was trained primarily in child psychology and neuropsychology at the University of Michigan. After graduation, I worked at Children's Hospital of Michigan in Detroit. I then moved to Washington, DC, where I took a position at the National Institute of Mental Health. My laboratory was dedicated to understanding severe neuropsychiatric illnesses, including schizophrenia and related disorders, from cognitive, genetic, and neurobiological perspectives. I was Chief of the Neurocognitive Section for two decades. Since leaving the NIMH, my work has transitioned to the study of aging and dementia at Columbia University. I have published over 200 scientific articles. A complete list of these is available in PubMed under "author"/ Goldberg TE.
Over the course of my career, I have always seen patients for clinical evaluations with a focus on neuropsychological assessment. I'm continuing to do clinical work here at Columbia University Medical Center in my Faculty Practice.
Schedule an Appointment
- NYP Employee Plan
- Behavioral Health Columbia University Employee Plan
Credentials & Experience
Education & Training
- PhD, University of Michigan
- Fellowship: Children's Hospital of Michigan
Development of Novel Measures of Cognition & Function for Alzheimer’s Disease Prevention Trials PI: Dr. Terry Goldberg, PhD
This study aims to determine how effective different cognitive and functional tests commonly used in clinical trials really are in testing memory, executive function, and attention. Eligible participants are non-cognitively impaired, healthy adults (ages 60-85 years) who will be followed over the course of 12 months. Participants will receive either novel more experimental measures that are computerized or the older more established measures that involve paper and pencil tests. This study is funded by the NIA, a division of the NIH.
For more information, please contact Sophie Bell at 646-774-8691.
“Novel Cognitive and Functional Measure for Alzheimer’s Disease Prevention Trials” (Federal Gov)
SEPT 1 2018-MAY 31 2023
ANTI-VIRAL THERAPY IN ALZHEIMER S DISEASE (Federal Gov)
Sep 15 2017 - May 31 2022
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT (Federal Gov)
Jul 15 2017 - Apr 30 2022
NOVEL COGNITIVE AND FUNCTIONAL MEASURES FOR ALZHEIMER S DISEASE PREVENTION TRIALS (Federal Gov)
Sep 1 2018 - May 31 2019
OLFACTORY DEFICITS AND DONEPEZIL TREATMENT IN COGNITIVELY IMPAIRED ELDERLY (Federal Gov)
Jun 15 2013 - May 31 2019